Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Resmed (RMD) and Sarepta Therapeutics (SRPT)
Raymond James & Associates Sells 10,648 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Raymond James & Associates lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 42.9% in the 3rd quarter, according to its most recent disclosure with the SEC. Th
Brinker Capital Investments LLC Acquires 150 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Brinker Capital Investments LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 3.6% during the third quarter, according to the company in its most recent 13F filing
SVB Leerink Reiterates Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating)'s stock had its "outperform" rating reaffirmed by stock analysts at SVB Leerink in a research note issued on Friday, Benzinga reports. They presently h
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and 2seventy Bio (TSVT)
9 Analysts Have This to Say About Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings52200Last 30D010001M
Sarepta Therapeutics Price Target Maintained With a $160.00/Share by SVB Leerink
Sarepta Therapeutics Price Target Maintained With a $160.00/Share by SVB Leerink
SVB Leerink Reiterates Outperform on Sarepta Therapeutics, Maintains $160 Price Target
SVB Leerink analyst Joseph Schwartz reiterates Sarepta Therapeutics with a Outperform and maintains $160 price target.
Connecticut Wealth Management LLC Invests $223,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Connecticut Wealth Management LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) in the 3rd quarter, according to the company in its most recent filing with
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shift From Loss To Profit
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Sarepta Therapeutics, Inc., a commercial-sta
Loading...
No Stock Yet